Hyphenate, an autonomous finance platform, secured $45 million in Series A funding following an 86-fold revenue increase and an 11-fold growth in customers over 12 months. Its AI-driven agents now handle 90% of routine finance work, such as invoicing and cash reconciliation, allowing finance teams to focus on strategic decisions. The funding will help expand its platform deeper into finance functions, aiming to fully automate finance operations while maintaining audit-ready accuracy. Major clients like Groupon and Synthesia are already adopting Hyphenate to replace legacy systems and improve efficiency.
Hyphenate's recent $45M Series A funding and rapid growth provide context for readers. For those following the Technology sector, 83 of 150 US stocks on Pluang rose today while 63 fell. Notable movers include NBIS at USD 157.92 (+3.03%, 51% Sell/49% Buy), HUBS at USD 256.67 (-2.77%, 100% Sell/0% Buy), and APLD at USD 18.32 (+2.75%, 24% Sell/76% Buy). Data as of Oct 27, 2026 18:51 WIB.
Alm. Brand A/S executed a share buy-back program from October 20 to 26, 2026, purchasing 1.81 million shares at an average price of DKK 17.41 each. This brings the total shares bought under the program to nearly 19.58 million, costing about DKK 324 m...
CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
eSoftware Associates advises defense contractors to carefully map controlled unclassified information (CUI) access permissions before licensing Microsoft 365 Copilot in the GCC High cloud environment. Moving to GCC High does not automatically grant c...
Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, inclu...
